The current diagnosis and clinical prognostic value of kidney dysfunction in patients with coronary heart disease


Cite item

Full Text

Abstract

The problem of kidney dysfunction and its impact on outcomes in different groups of cardiac patients continue to being widely used. Kidney dysfunction is associated with a number of traditional cardiovascular risk factors. The use of new biomarkers, cystatin C in particular, to identify kidney injury can contribute to the improvement of early prediction of a risk for renal failure (RF). Cystatin C satisfies many characteristics as an ideal biomarker that can assist in not only detecting the early forms of kidney injury, but also in assessing the risk of RF, the needs for renal replacement therapy, and the risk of death in intensive care unit patients in cardiac clinics. Kidney involvement in many diseases, including those that are not initially regarded as renal, necessitates the elaboration of uniform approaches to managing patients with identified chronic RF, especially to the early prevention and treatment of its complications, such as anemia, phosphorus-calcium metabolic disorders, which substantially worsen the prognosis of other diseases.

Full Text

Современная диагностика и клинико-прогностическое значение дисфункции почек у больных ишемической болезнью сердца. - Аннотация. Проблема дисфункции почек и ее влияние на исходы у различных групп кардиологических пациентов продолжает широко обсуждаться. Дисфункция почек ассоциирована с рядом традиционных факторов риска развития сердечно-сосудистых осложнений. Использование "новых" биомаркеров, в частности цистатина С, для выявления повреждения почек может способствовать усовершенствованию раннего прогнозирования риска почечной недостаточности (ПН). Цистатин С удовлетворяет многим характеристикам "идеального" биомаркера, при помощи которого можно не только выявлять ранние формы повреждения почек, но и оценивать риск развития ПН, потребности в терапии, замещающей функцию почек, и риск смерти у пациентов отделений интенсивной терапии кардиологических клиник. Вовлечение почек при многих заболеваниях, в том числе исходно не считающихся почечными, делает необходимой разработку единых подходов к ведению пациентов с выявленной хронической ПН, особенно в плане раннего предупреждения и лечения ее осложнений: анемии, нарушений фосфорно-кальциевого обмена, существенно ухудшающих прогноз других заболеваний.
×

References

  1. Кардиоваскулярная профилактика. Национальные рекомендации. Кардиоваск тер и проф 2011; 6 (Приложение 2): 1-64.
  2. Cardiovascular diseases. Fact sheet № 317. WHO. September 2011. http://www.who.int/mediacentre/factsheets/fs317/en
  3. Томилина Н.А. Проблема сердечно-сосудистых заболеваний при хронической почечной недостаточности. Нефрол диал 2003; 1: 15-24.
  4. Макарычева О.В., Хмара Т.Н., Якушева Н.В. и др. Дисфункция почек при поступлении в блок кардиореанимации - фактор риска госпитальной летальности у больных с острым инфарктом миокарда с подъемом сегмента ST. Креатив кардиол 2010; 2: 35-40.
  5. Santopinto J.J., Fox K., Goldberg R.J. et al. on behalf of the GRACE Investigators. Creatinine clearance and adverse hospital outcomes in patients with acute coronary syndromes: findings from the global registry of acute coronary events (GRACE). Heart 2003; 89: 1003-1008.
  6. Marenzi G., Assanelli E., Campodonico J. et al. Acute kidney injury in ST-segmrnt elevation acute myocardial infarction complicated by cardiogenic shock at admission. Crit Care Med 2010; 38: 438-444.
  7. Masoudi F.A., Plomondon M.E., Magid D.J. et al. Renal insufficiency and mortality from acute coronary syndromes. Am Heart J 2004; 147 (4): 623-629.
  8. Mueller C., Neumann F.-J., Perruchoud A.P., Buettner H.J. Renal function and long term mortality after unstable angina/non-ST segment elevation myocardial infarction treated very early and predominantly with percutaneous coronary intervention. Heart 2004; 90 (8): 902-907.
  9. Каретникова В.Н., Зыков М.В., Кашталап В.В. и др. Значение почечной дисфункции для госпитального прогноза больных инфарктом миокарда с подъемом сегмента ST. Сердце 2013; 5: 284-289.
  10. Ефремова Е.В., Шутов А.М., Сабитов И.А. Коморбидность и приверженность к лечению при хронической сердечной недостаточности. Сердеч недостат 2013; 1: 40-46.
  11. Gleeson T.G., Bulugahapitiya S. Contrast-induced nephropathy. AJR Am J Roentgenol 2004; 183: 1673-1689.
  12. Han Y., Zhu G., Han L. et al. Short-term rosuvastatin therapy for prevention of contrast-induced acute kidney injury in patients with diabetes and chronic kidney disease. J Am Coll Cardiol 2013. http://dx.doi.org/10.1016/j.jacc.2013.09.017.
  13. Nauck M.A., Barnett A.H., Filetti S., Tambascia M.A. The diabetes patient with renal impairment: hyperglycemia management across the spectrum of CKD. Medscape Education Diabetes & Endocrinology 2012. http://www.medscape.org/viewarticle/772418_transcript
  14. Scheen A.J. Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease. Expert Opin Drug Metab Toxicol 2013; 9 (5): 529-550.
  15. Scheen A.J. How I treat ... with metformin a diabetic patient with moderate renal insufficiency. Rev Med Liege 2013; 68 (4): 190-195.
  16. Poli D., Antonucci E., Zanazzi M. et al. Impact of glomerular filtration estimate on bleeding risk in very old patients treated with vitamin K antagonists. Results of EPICA study on the behalf of FCSA (Italian Federation of Anticoagulation Clinics). Thromb Haemost 2012; 107 (6): 1100-1106.
  17. Kubitza D., Becka M., Wensing G. et al. Safety, pharmacodynamics, and pharmacogenetics of BAY 59-7939-an oral, direct factor Xa inhibitor-after multiple dosing in healthy male subjects. Eur J Clin Pharmacol 2005; 61: 873-880.
  18. Kubitza D., Becka M., Roth A., Mueck W. Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects. Curr Med Res Opin 2008; 24: 2757-2765.
  19. Fox K.A., Piccini J.P., Wojdyla D. et al. Preventation of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J 2011; 32: 2387-2394.
  20. Thakar C.V., Worley S., Arrigain S. et al. Influence of renal dysfunction on mortality after cardiac surgery: modifying effect of preoperative renal function. Kidney Int 2005; 67: 1112-1119.
  21. Levey A.S., Bosch J.P., Lewis J.B. et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130 (6): 461-470.
  22. Wilson B., Sontrop J.M., Clark W.F. Choice of GFR estimating equation influences dialysis initiation and mortality. Nephrol Nurs J 2013; 40 (4): 339-346.
  23. Collins A.J., Li S., Gilbertson D.T. et al. Chronic kidney disease and cardiovascular disease in the Medicare population. Kidney Int 2003; 64 (87): 24-31.
  24. Шафранская К.С., Кашталап В.В., Кузьмина А.А. и др. Роль цистатина С в прогнозировании риска развития неблагоприятных исходов коронарного шунтирования в госпитальном периоде. Рос кардиол журн 2013; 3: 45-50.
  25. Nickolas T.L., Barasch J., Devarajan P. Biomarkers in acute and chronic kidney disease. Curr Opin Nephrol Hypertens 2008; 17: 127-132.
  26. Devarjan P. Emerging biomarkers of acute kidney injuri. Contrib Nephrol 2007; 156: 203-212.
  27. Gracie J.A., Robertson S.E., McInnes I.B. Interleukin-18. J Leukoc Biol 2003; 73: 213-224.
  28. Walker M., Whincup P.H., Shaper A.G. The British Regional Heart Study 1975-2004. Int J Epidemiol 2004; 33: 1185-1192.
  29. Koenig W., Khuseyinova N., Baumert J. Increased concentrations of C-reactive protein and IL-6 but not IL-18 are independently associated with incident coronary events in middle-aged men and women: results from the MONICA/KORA Augsburg case-cohort study, 1984-2002. Arterioscler Thromb Vasc Biol 2006; 26: 2745-2751.
  30. Danesh J., Wheeler J.G., Hirschfield G.M. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004; 350: 1387-1397.
  31. Mallat Z., Corbaz A., Scoazec A. Expression of interleukin-18 in human atherosclerotic plaques and relation to plaque instability. Circulation 2001; 104: 1598-1603.
  32. Parikh C.R., Jani A., Melnikov V.Y. et al. Urinary interleukin-18 is a marker of human acute tubular necrosis. Am J Kidney Dis 2004; 43 (3): 405-414.
  33. Ichimura T., Bonventre J.V., Bailly V. et al. Kidney injury molecule-1 (KIM-1), a putative epithelial cell adhesion molecule containing a novel immunoglobylin domain, is up-regulated in renal cells after injury. J Biol Chem 1998; 273 (7): 4135-4142.
  34. Vaidya V.S., Ford G.M., Waikar S.S. et al. A rapid urine test for early detection of kidney injury. Kidney Int 2009; 76 (1): 108-114.
  35. Rees J., Kain R. KIM-1/Tim-1: from biomarker to therapeutic target. Nephrol Dial Transplant 2008; 23: 3394-3396.
  36. Kjeldsen L., Cowland J.B., Borregard N. Human neitrophil gelatinase-associated lipocalin and homologous proteins in rat and mouse. Biochim Biophys Acta 2000; 1482: 272-283.
  37. Haase-Fielitz A., Bellomo R., Devarjan P. The predictive performance of plasma neitrophil gelatinase-associated lipocalin (NGAL) increases with grade of acute kidney injury. Nephrol Dial Transplant 2009; 24: 3349-3354.
  38. Плющ М.Г., Ярустовский М.Б., Абрамян М.В. и др. Нейтрофильно-желатиназоассоциированный липокалин - ранний маркер острого повреждения почек у пациентов после открытых операций на сердце и сосудах. Бюл НЦССХ им. А.Н. Бакулева РАМН 2012; 3: 53-59.
  39. Chew J.SC., Saleem M., Florkowski C.M., George P.M. Cystatin C - a paradigm of evidence based laboratory medicine. Clin Biochem 2008; 29: 47-62.
  40. Lofberg H., Grubb A. Quantitation of gamma-trace in human biological fl uids: indications for production in the central nervous system. Scand J Clin Lab Invest 1979; 39: 619-626.
  41. Grubb A., Simonsen O., Sturfelt G. et al. Serum concentration of cystatin C, factor D and α2-microglobulin as a measure of glomerular filtration rate. Acta Med Scand 1985; 218: 499-503.
  42. Gosling P., Czyz J., Nightingale P., Manji M. Microalbuminuria in the intensive care unit: сlinical correlates and association with outcomes in 431 patients. Crit Care Med 2006; 34 (8): 2158-2166.
  43. Foley R.N., Wang C., Collins A.J. Cystatin C, mortality risk and clinical triage in US adults: threshold values and hierarchical importance. Nephrol Dial Transplant 2011; 26 (6): 1831-1837.
  44. Muntner P., Winston J., Uribarri J. Overweight, obesity, and elevated serum cystatin C levels in adults in the United States. Am J Med 2008; 121: 341-348.
  45. Walczak K., Rośniak-Bąk K., Paradowski M., Moczulski D. Cystatin C as a marker of renal function in diabetic kidney disease. Diabet Dośw Klin 2009; 9 (2): 69-72.
  46. Pasupathy P. Dhanalakshmi G., Ponnusha B.S., Ambika A. Cystatin C: а novel marker for renal failure. Int J Cur Bio Med Sci 2011; 1 (3): 120-125.
  47. Кардаш О.Ф. Реферат по теме 259. http://www.cardio.by/page/view/theme259
  48. Ребров А.П., Куклина А.Л. Цистатин С и поражение органов-мишеней при артериальной гипертензии. Клин нефрол 2013; 2: 19-24.
  49. Zhao C., Yang L., Mao L. et al. Cystatin C associates with the prediction of in-stent restenosis among patients receiving stent implantation: results of the 1-year follow-up. Coron Artery Dis 2013; 24 (5): 357-360.
  50. Zhang J.B., Jü X.H., Wang J. et al. Serum cystatin C and cerebral microbleeds in patients with acute cerebral stroke. J Clin Neurosci 2013. http://dx.doi.org/10.1016/j.jocn.2013.04.014

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2014 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies